Understand anaphylactic reaction, also known as anaphylaxis or anaphylactic shock, with this guide for healthcare professionals. Learn about clinical documentation best practices, medical coding for anaphylaxis (ICD-10), and effective diagnosis of this severe allergic reaction. Find information on symptoms, treatment, and management of anaphylactic reactions in a clinical setting.
Severe, potentially life-threatening allergic reaction requiring immediate medical attention.
Hives, swelling, difficulty breathing, low blood pressure, dizziness, vomiting, weak pulse.
Exposure to allergens like foods, insect stings, medications, or latex in community or healthcare settings.
Complete code families applicable to T78.2
| Description | When to use |
|---|---|
| Severe allergic reaction, rapid onset. | Use for immediate, life-threatening hypersensitivity reactions to allergens. |
| Allergic reaction, localized or systemic. | Use for any allergic reaction not immediately life-threatening. Exclude anaphylaxis. |
| Hypersensitivity to a specific substance. | Use for known or suspected allergy to a particular allergen. May or may not manifest as a reaction. |
Coding anaphylaxis requires specific documentation of cause and manifestation for accurate code assignment (e.g., T78.00XA vs. T78.2XXA). CDI can query for details.
Underlying conditions contributing to anaphylaxis (e.g., food allergy, insect sting) must be coded. Overlooking these impacts risk adjustment and reimbursement.
Insufficient documentation of anaphylaxis severity (mild, moderate, severe) can lead to coding errors and denials during audits. CDI should ensure clear severity descriptions.
Sudden onset of symptoms after exposure?
Respiratory compromise or hypotension?
Skin or mucosal involvement (hives, swelling)?
Involvement of at least two organ systems?
Patient presented with acute onset of anaphylaxis, exhibiting classic symptoms consistent with a systemic type I hypersensitivity reaction. The suspected trigger was [insert suspected trigger, e.g., ingestion of peanuts, bee sting, administration of penicillin]. Onset of symptoms occurred within [timeframe, e.g., minutes, seconds] of exposure. Clinical manifestations included urticaria, pruritus, angioedema involving the [location of angioedema, e.g., face, lips, tongue], and respiratory distress characterized by [description of respiratory distress, e.g., dyspnea, wheezing, stridor]. Vital signs at presentation revealed [document vital signs, e.g., hypotension, tachycardia, oxygen saturation]. The patient met diagnostic criteria for anaphylactic shock based on the presence of both skin/mucosal involvement and respiratory compromise. Differential diagnoses considered included other causes of allergic reactions, angioedema, and respiratory distress. Treatment was initiated immediately with intramuscular epinephrine 1:1000 concentration [dosage]. Supplemental oxygen was administered via [method of oxygen administration, e.g., nasal cannula, non-rebreather mask] to maintain oxygen saturation above 95%. Intravenous access was established, and normal saline infusion was initiated. Patient response to treatment was [describe response, e.g., rapid, gradual] with resolution of symptoms. The patient was monitored for biphasic anaphylaxis and discharged with a prescription for an epinephrine auto-injector and instructions on its proper use. Patient education regarding allergen avoidance and anaphylaxis action plan was provided. ICD-10 code T78.00XA (initial encounter) was assigned. Follow-up with an allergist is recommended for further evaluation and potential allergy testing.
Differentiating between a mild allergic reaction and anaphylaxis requires careful assessment of symptom severity and onset. While mild reactions may present with localized urticaria or pruritus, anaphylaxis involves two or more organ systems and often manifests as rapid-onset hypotension, dyspnea, oropharyngeal angioedema, and/or persistent gastrointestinal symptoms. According to the World Allergy Organization guidelines, even one symptom like hypotension after exposure to a known allergen can be sufficient for the diagnosis of anaphylaxis. Accurate and rapid differentiation is crucial, as anaphylaxis is a medical emergency requiring immediate intramuscular epinephrine administration. Explore how S10.AI can help streamline your anaphylaxis diagnosis and management protocols.
Managing anaphylaxis in resource-limited settings with limited access to epinephrine auto-injectors presents significant challenges. While intramuscular epinephrine is the first-line treatment, improvisation may be necessary. Secure the patient's airway, administer supplemental oxygen, and establish intravenous access for fluid resuscitation. If epinephrine is unavailable, consider alternative vasopressors, such as norepinephrine or dopamine, while keeping in mind their potential side effects. Antihistamines and corticosteroids can be used as adjunctive therapy but are not substitutes for epinephrine. Early transfer to a higher level of care is critical. Consider implementing training programs focused on recognizing and managing anaphylaxis in low-resource environments. Learn more about the practical strategies for anaphylaxis management in diverse settings.
Long-term anaphylaxis follow-up care is crucial for preventing future episodes. All patients should receive a prescription for epinephrine auto-injectors and thorough education on their use, storage, and the signs and symptoms of anaphylaxis. Referral to an allergist for comprehensive allergy testing and personalized management plans is essential. This includes identifying the trigger allergen(s) and discussing allergen avoidance strategies. Shared decision-making regarding immunotherapy should also be a component of the long-term plan. Explore how S10.AI can support individualized anaphylaxis follow-up care to improve patient outcomes and reduce the risk of future reactions.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.